SCB-1019 is under clinical development by Clover Biopharmaceuticals and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase I drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SCB-1019 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SCB-1019 overview

SCB-1019 is under development for the prevention of respiratory syncytial virus A and respiratory syncytial virus B infection. The vaccine candidate comprises of trimerized RSV fusion glycoprotein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). It is being developed based on Trimer-Tag technology.

Clover Biopharmaceuticals overview

Clover Biopharmaceuticals (Clover) is a biotechnology company that focuses on discovering, developing and commercializing biologic therapies. The company’s pipeline products include SCB-2019 (CpG 1018/Alum), SCB-2020S (CAS-1), Bivalent COVID-19 Vaccine (SCB-2019 + SCB-2022B), Rabies Vaccine, RSV Vaccine, Influenza Vaccine, SCB-313, SCB-219M. It utilizes its proprietary technology platform Trimer-Tag to develop vaccines for rabies, influenza, respiratory syncytial virus (RSV) and human immunodeficiency virus (HIV). The company also carries out research and development on therapies for oncology and autoimmune diseases. Clover is headquartered in Shanghai, China.

For a complete picture of SCB-1019’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.